Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms

Abstract Intestinal epithelial cell damage caused by SARS-CoV-2 infection was thought to be associated with gastrointestinal symptoms and decreased fecal consistency. The association of the gastrointestinal symptoms with the COVID-19-mediated inflammatory response triggered by the gastrointestinal i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hajar Shokri-Afra, Ahmad Alikhani, Bahman Moradipoodeh, Farshid Noorbakhsh, Hafez Fakheri, Hemen Moradi-Sardareh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e3830e34d4924d4a8b30f4751c3ab77d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e3830e34d4924d4a8b30f4751c3ab77d
record_format	dspace
spelling	oai:doaj.org-article:e3830e34d4924d4a8b30f4751c3ab77d2021-11-14T12:18:19ZElevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms10.1038/s41598-021-01231-42045-2322https://doaj.org/article/e3830e34d4924d4a8b30f4751c3ab77d2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01231-4https://doaj.org/toc/2045-2322Abstract Intestinal epithelial cell damage caused by SARS-CoV-2 infection was thought to be associated with gastrointestinal symptoms and decreased fecal consistency. The association of the gastrointestinal symptoms with the COVID-19-mediated inflammatory response triggered by the gastrointestinal immune system was investigated in this paper. Intestinal inflammation marker fecal calprotectin along with serum calprotectin and other inflammatory markers were measured in COVID-19 cases with and without GI manifestations as well as healthy individuals. Analyses were performed to compare COVID-19 patient subgroups and healthy controls and examine the relationship between fecal and serum calprotectin levels with gastrointestinal symptoms and disease severity. COVID-19 patients (n = 70) were found to have markedly elevated median levels of fecal (124.3 vs. 25.0 µg/g; P < 0/0001) and serum calprotectin (3500 vs. 1060 ng/mL; P < 0/0001) compared with uninfected controls. Fecal and serum calprotectin levels were not significantly different between COVID-19 patients who displayed GI symptoms and those who did not. Compared with other acute phase markers, both fecal and serum calprotectin were superior in identifying COVID-19 patients who progressed to severe illness. Although the progression of COVID-19 disease is marked by an elevation of fecal and serum calprotectin, gastrointestinal symptoms or diarrhea were not correlated with calprotectin increase level.Hajar Shokri-AfraAhmad AlikhaniBahman MoradipoodehFarshid NoorbakhshHafez FakheriHemen Moradi-SardarehNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hajar Shokri-Afra Ahmad Alikhani Bahman Moradipoodeh Farshid Noorbakhsh Hafez Fakheri Hemen Moradi-Sardareh Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms
description	Abstract Intestinal epithelial cell damage caused by SARS-CoV-2 infection was thought to be associated with gastrointestinal symptoms and decreased fecal consistency. The association of the gastrointestinal symptoms with the COVID-19-mediated inflammatory response triggered by the gastrointestinal immune system was investigated in this paper. Intestinal inflammation marker fecal calprotectin along with serum calprotectin and other inflammatory markers were measured in COVID-19 cases with and without GI manifestations as well as healthy individuals. Analyses were performed to compare COVID-19 patient subgroups and healthy controls and examine the relationship between fecal and serum calprotectin levels with gastrointestinal symptoms and disease severity. COVID-19 patients (n = 70) were found to have markedly elevated median levels of fecal (124.3 vs. 25.0 µg/g; P < 0/0001) and serum calprotectin (3500 vs. 1060 ng/mL; P < 0/0001) compared with uninfected controls. Fecal and serum calprotectin levels were not significantly different between COVID-19 patients who displayed GI symptoms and those who did not. Compared with other acute phase markers, both fecal and serum calprotectin were superior in identifying COVID-19 patients who progressed to severe illness. Although the progression of COVID-19 disease is marked by an elevation of fecal and serum calprotectin, gastrointestinal symptoms or diarrhea were not correlated with calprotectin increase level.
format	article
author	Hajar Shokri-Afra Ahmad Alikhani Bahman Moradipoodeh Farshid Noorbakhsh Hafez Fakheri Hemen Moradi-Sardareh
author_facet	Hajar Shokri-Afra Ahmad Alikhani Bahman Moradipoodeh Farshid Noorbakhsh Hafez Fakheri Hemen Moradi-Sardareh
author_sort	Hajar Shokri-Afra
title	Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms
title_short	Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms
title_full	Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms
title_fullStr	Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms
title_full_unstemmed	Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms
title_sort	elevated fecal and serum calprotectin in covid-19 are not consistent with gastrointestinal symptoms
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e3830e34d4924d4a8b30f4751c3ab77d
work_keys_str_mv	AT hajarshokriafra elevatedfecalandserumcalprotectinincovid19arenotconsistentwithgastrointestinalsymptoms AT ahmadalikhani elevatedfecalandserumcalprotectinincovid19arenotconsistentwithgastrointestinalsymptoms AT bahmanmoradipoodeh elevatedfecalandserumcalprotectinincovid19arenotconsistentwithgastrointestinalsymptoms AT farshidnoorbakhsh elevatedfecalandserumcalprotectinincovid19arenotconsistentwithgastrointestinalsymptoms AT hafezfakheri elevatedfecalandserumcalprotectinincovid19arenotconsistentwithgastrointestinalsymptoms AT hemenmoradisardareh elevatedfecalandserumcalprotectinincovid19arenotconsistentwithgastrointestinalsymptoms
_version_	1718429320335065088

Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms

Ejemplares similares